Inclusion Criteria:

          1. Patients with advanced and/or metastatic histologically solid tumors with evidence of
             active disease, who have been treated with a minimum of one line of systemic therapy
             in the metastatic setting but no more than three prior systemic therapies (for part 1
             dose escalation), or no more than two prior systemic therapies (for part 2 cohorts
             expansion).

          2. At least 18 years of age.

          3. ECOG performance status of ≤1.

          4. Adequate organ function

        Exclusion Criteria:

          1. For patients with NSCLC:

             a. Known mutation in the epidermal growth factor receptor (EGFR), anaplastic lymphoma
             kinase (ALK) gene rearrangements, ROS-1 alterations or BRAF mutations

          2. For patient with Hepatocellular carcinoma:

               1. Hepatic encephalopathy in the past 12 months.

               2. Ascites that requires repeated paracentesis in the past 2 months.

               3. Main portal vein thrombosis.

               4. Active or prior history of gastrointestinal bleeding in the past 12 months.

               5. Prior hepatic transplantation.

          3. Patients with known spinal cord compression.

          4. Symptomatic, untreated, or actively progressing central nervous system (CNS)
             metastases.